Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronavirus and infectious disease therapeutics - Mannin Research/Q BioMed

Drug Profile

Research programme: coronavirus and infectious disease therapeutics - Mannin Research/Q BioMed

Latest Information Update: 06 Feb 2020

At a glance

  • Originator Mannin Research; Q BioMed
  • Class Anti-infectives; Antivirals
  • Mechanism of Action TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections; Infections

Most Recent Events

  • 22 Apr 2020 Q BioMed and Mannin plans clinical trials for COVID-2019 infections in 2020
  • 04 Feb 2020 Early research in COVID-2019-infections in Canada (unspecified route)
  • 04 Feb 2020 Early research in COVID-2019-infections in USA (unspecified route)

Development Overview

Introduction

Therapeutics targeted against COVID-2019 infections (originated in Wuhan, China) and other infectious diseases [Infections in development table], are being jointly developed by Q BioMed and Mannin Research (research partner of Q BioMed). The development is utilising Mannin's lead research platform, which targets the activation of the Angiopoietin-Tie2 signaling pathway. The therapeutics will constitute a potential adjunct treatment against coronavirus. The collaborative endeavor seeks to augment the survival rate of patients by lowering endothelial dysfunction and severity of infectious diseases, facilitated by an enhancement of host-directed therapeutic response. Early research is underway in the US and Canada.

Key Development Milestones

As at February 2020, early research for the treatment of COVID-2019 infections and other infections, was underway in the US and Canada [1] .

Financing information

In April 2020, Q BioMed entered into a financial restructuring and received additional $US4 000 000. The company intends to use this funding to advance pipeline assets including a potential treatment for COVID-19, influenza and others, liver cancer therapy Uttroside B and rare disease drug development in non-verbal autism spectrum disorders [2] .

In February 2020, Q BioMed reported the submission of a funding application by Mannin, to the Small Business Technology Transfer Grant administered by the U.S. National Institutes of Health, for the investigation of specific applications of Mannin's therapeutic platform [1] .

In September 2019, Mannin became the recipient of a grant totaling approximately $US7.7 million, awarded by the German state of Saxony. The grant is intended for the advancement of Mannin's novel therapeutics, responsible for lowering endothelial dysfunction and loss of endothelial barrier integrity, implicated in viral and bacterial infections, leading to acute and severe lung injury [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Anti-infectives, Antivirals
  • Target TIE-2 receptor
  • Mechanism of Action TIE-2 receptor agonists
  • WHO ATC code

    J (Anti-infectives For Systemic Use)

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J (General Anti-Infectives Systemic)

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research Canada, USA unspecified / unspecified Mannin Research, Q BioMed 04 Feb 2020
Infections - - Research Canada, USA unspecified / unspecified Mannin Research, Q BioMed 04 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Mannin Research Originator Canada
Q BioMed Originator USA
Q BioMed Owner USA
Mannin Research Owner Canada

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Trial Update Q BioMed and Mannin plans clinical trials for COVID-2019 infections in 2020 [3] 27 Apr 2020

Development History

Event Date Update Type Comment
22 Apr 2020 Trial Update Q BioMed and Mannin plans clinical trials for COVID-2019 infections in 2020 [3] Updated 27 Apr 2020
04 Feb 2020 Phase Change Early research in COVID-2019-infections in Canada (unspecified route) [1] Updated 06 Feb 2020
04 Feb 2020 Phase Change Early research in COVID-2019-infections in USA (unspecified route) [1] Updated 06 Feb 2020
04 Feb 2020 Phase Change Early research in Infections in Canada (unspecified route) [1] Updated 06 Feb 2020
04 Feb 2020 Phase Change Early research in Infections in USA (unspecified route) [1] Updated 06 Feb 2020

References

  1. Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases.

    Media Release
  2. Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion.

    Media Release
  3. Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics.

    Media Release
Back to top